A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Nemolizumab (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Acronyms Nemo CKDaP; NIKAIA
- Sponsors Galderma Research & Development
- 05 Apr 2024 Status changed from active, no longer recruiting to completed.
- 22 Jan 2024 Planned End Date changed from 3 Jan 2024 to 19 Feb 2024.
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.